An atlas of histone deacetylase expression in breast cancer: Fluorescence methodology for comparative semi-quantitative analysis

American Journal of Translational Research

Volumn 4, Issue 1, 2012, Pages 24-43

  Ververis, Katherine ^a,b   Karagiannis, Tom C ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast cancer; Chromatin; Histone acetylation; Histone deacetylase inhibitor; Immunofluorescence

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; COMPUTER PROGRAM; FLUORESCENCE; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTRADUCTAL CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; T CELL LYMPHOMA; VALIDATION STUDY; WESTERN BLOTTING; YEAST;

MAMMALIA;

EID: 84856623129     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-626.
2. Cyr AR, Domann FE. The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal 2011; 15: 551-589.
3. Wade PA, Pruss D and Wolffe AP. Histone acetylation: chromatin in action. Trends Biochem Sci 1997; 22: 128-132.
4. Glozak MA, Sengupta N, Zhang X and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.
5. Cheung P, Allis CD and Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 2000; 103: 263-271.
6. Hildmann C, Riester D and Schwienhorst A. Histone deacetylases-an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol 2007; 75: 487-497.
7. Clayton AL, Hazzalin CA and Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006; 23: 289-296.
8. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J and Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell 2007; 131: 633-636.
9. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96: 293-304.
10. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9: 809-824.
11. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
12. Xu WS, Parmigiani RB and Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
13. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L and Sternglanz R. The silencing protein SIR2 and its homologs are NADdependent protein deacetylases. Proc Natl Acad Sci USA 2000; 97: 5807-5811.
14. Haigis MC, Guarente LP. Mammalian sirtuinsemerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-2921.
15. Landry J, Slama JT and Sternglanz R. Role of NAD(+) in the deacetylase activity of the SIR2- like proteins. Biochem Biophys Res Commun 2000; 278: 685-690.
16. Gregoretti IV, Lee YM and Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
17. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
18. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
19. Yang XJ, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 2003; 13: 143-153.
20. Martin M, Kettmann R and Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007; 26: 5450-5467.
21. Witt O, Deubzer HE, Milde T and Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
22. Dokmanovic M, Clarke C and Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989.
23. Mai A, Rotili D, Valente S and Kazantsev AG. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 2009; 15: 3940-3957.
24. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010; 1799: 717-725.
25. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107: 600-608.
26. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749.
27. Gao YS, Hubbert CC and Yao TP. The microtubule- associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem 2010; 285: 11219-11226.
28. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-458.
29. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A and Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738.
30. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
31. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009; 45: 787-795.
32. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M and Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-774.
33. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y and Inoue S. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009; 69: 2935-2940.
34. Meng Q, Chen X, Sun L, Zhao C, Sui G and Cai L. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. Mol Cell Biochem 2011; 348: 165-171.
35. Rey M, Irondelle M, Waharte F, Lizarraga F and Chavrier P. HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur J Cell Biol 2011; 90: 128-135.
36. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M and Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptorpositive breast cancer. Oncogene 2005; 24: 4531-4539.
37. Wang KH, Kao AP, Chang CC, Lee JN, Hou MF, Long CY, Chen HS and Tsai EM. Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 2010; 9: 288.
38. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S and Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10: 6962-6968.
39. Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG and Kang J. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011; 25: 1677-1681.
40. Hsieh TH, Tsai CF, Hsu CY, Kuo PL, Lee JN, Chai CY, Wang SC and Tsai EM. Phthalates induce proliferation and invasiveness of estrogen receptor- negative breast cancer through the AhR/ HDAC6/c-Myc signaling pathway. FASEB J 2011.
41. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM and Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005; 90: 15-23.
42. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
43. Crow MJ, Grant G, Provenzale JM and Wax A. Molecular imaging and quantitative measurement of epidermal growth factor receptor expression in live cancer cells using immunolabeled gold nanoparticles. AJR Am J Roentgenol 2009; 192: 1021-1028.
44. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168-176.
45. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS and Yu Y. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer 2007; 120: 1664-1668.
46. Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ and Zhong XY. Epigenetic therapy for breast cancer. Int J Mol Sci 2011; 12: 4465-4487.
47. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ and Tofilon PJ. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004; 64: 316-321.